LONDON--(BUSINESS WIRE)-- Citi, acting through Citibank N.A., has been appointed by NuCana plc (“NuCana”) as depositary bank for its American Depositary Receipt (“ADR”) programme. NuCana’s ADRs trade on the NASDAQ Global Select Market under the symbol “NCNA.” Each ADR represents one ordinary share of NuCana
“Citi is delighted to be appointed by NuCana as depositary bank for its NASDAQ listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “We are confident that we will be able to assist NuCana in expanding their investor outreach through the support of our Investor Relations Advisory team and our unparalleled equity distribution network.”
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. NuCana’s most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin® is currently being evaluated in clinical studies across several solid tumor indications, including ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumor cancers.
Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003005646/en/